[ 225 Ac]Ac‐PSMA for the treatment of metastatic castration‐resistant prostate cancer: A systematic review and meta‐analysis
European Journal of Clinical Investigation · 2025-05 · 55 (5)
DOI: 10.1111/eci.14358 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 18.11.2024. Verfasst von Maria Luisa Garo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biostatistic Unit, Mathsly Research, Rome, Italy. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Actinium, Radiopharmaceuticals. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background
Approximately 10%–20% of prostate cancers progress to metastatic and castration‐resistant forms (mCRPC). Radioligand (RLT) therapy with [ 177 Lu]Lu‐prostate‐specific membrane antigen (PSMA) is an approved treatment for metastasized mCRPC. Moreover, Actinium‐225 ( 225 Ac), an alpha‐emitter isotope, has also been used to label PSMA and, recently, to treat mCRPC patients with encouraging results. However, robust clinical data on [ 225 Ac]Ac‐PSMA therapy and its comparison with [ 177 Lu]Lu‐PSMA are still limited. Our aim was to evaluate the role of [ 225 Ac]Ac‐PSMA in treating mCRPC and compare it with conventional [ 177 Lu]Lu‐PSMA therapy.
Methods
A systematic search was performed in PubMed, Web of Science, Scopus and the Cochrane Register of Controlled Trials from June 2023 to January 2024. This work was conducted in accordance with PRISMA guidelines.
Results
After screening and study selection according to PRISMA guidelines, 11 studies were included, 9 of which focused on [ 225 Ac]Ac‐PSMA only and two on tandem therapy ([ 225 Ac]Ac‐PSMA/[ 177 Lu]Lu‐PSMA). Overall, the pooled proportion of PSA decline in patients was .85 (95% CI: .79–.91, p < .001); patients pretreated with [ 177 Lu]Lu‐PSMA achieved a pooled proportion of PSA decline of .90 (95% CI: .82–.97, p < .001). In patients treated with tandem therapy, PSA decline was observed in approximately 90% of them, while PSA response rates above 50% ranged from 53.3% to 65%. Xerostomia was the most frequently reported side effect, along with anaemia, thrombocytopenia and nephrotoxicity.
Conclusions
Overall, the main results of our study showed that [ 225 Ac]Ac‐PSMA‐617 had a significant therapeutic effect on mCRPC with an acceptable toxicity level. The latter, however, appears greater than with [ 177 Lu]Lu‐PSMA‐617. In future studies, an adequate analysis of the incidence of side effects associated with [ 225 Ac]Ac‐PSMA should be performed to evaluate the role of cumulative toxicity of earlier treatments and the higher frailty of heavily pretreated patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biostatistic Unit, Mathsly Research, Rome, Italy.
- Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia.
- School of Medicine, University of Zagreb, Zagreb, Croatia.
- Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria S. Orsola, Bologna, Italy.
- Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
- Nuclear Medicine, Gruppo Ospedaliero Moncucco, Clinica Moncucco, Lugano, Switzerland.
ORCID-Profile: Maria Luisa Garo
Zitieren
APA
Garo, M. L., Ovčariček, P. P., Fanti, S., & Giovanella, L. (2025). [ 225 Ac]Ac‐PSMA for the treatment of metastatic castration‐resistant prostate cancer: A systematic review and meta‐analysis. European Journal of Clinical Investigation, 55(5). https://doi.org/10.1111/eci.14358
Vancouver
Garo ML, Ovčariček PP, Fanti S, Giovanella L. [ 225 Ac]Ac‐PSMA for the treatment of metastatic castration‐resistant prostate cancer: A systematic review and meta‐analysis. European Journal of Clinical Investigation. 2025;55(5). doi:10.1111/eci.14358
BibTeX
@article{Garo2025,
author = {Garo, Maria Luisa and Ovčariček, Petra Petranović and Fanti, Stefano and Giovanella, Luca},
title = {[ 225 Ac]Ac‐PSMA for the treatment of metastatic castration‐resistant prostate cancer: A systematic review and meta‐analysis},
journal = {European Journal of Clinical Investigation},
year = {2025},
volume = {55},
number = {5},
doi = {10.1111/eci.14358}
}
EUVIMED